Form 4: Amylyx CLO Sells Shares for Tax Obligations
Insider Transaction Report
Amylyx Pharmaceuticals' Chief Legal Officer, Gina Mazzariello, sold 8,828 shares of common stock at a weighted average price of $14.5751 to cover tax withholding obligations.
Summary
- Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, Inc. (AMLX), reported a transaction on September 30, 2025.
- The transaction involved the disposition of 8,828 shares of Amylyx Pharmaceuticals common stock.
- The shares were sold at a weighted average price of $14.5751 per share, with individual sales ranging from $14.355 to $15.075.
- The sale was mandatory, executed to cover tax withholding obligations associated with the vesting of restricted stock units, and was not at the discretion of the reporting person.
- Following this transaction, Gina Mazzariello beneficially owns 148,141 shares of common stock directly.
Sentiment
Score: 5
Explanation: The sentiment is neutral. The transaction is a mandatory sale to cover tax withholding obligations upon the vesting of restricted stock units, which is a common and non-discretionary event for executives and does not reflect a change in management's confidence in the company.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This filing reports a routine insider transaction related to tax obligations, which is common for executives receiving equity compensation. It does not provide information relevant to broader industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: The sale represents a minor dilution of outstanding shares, but is a routine event for equity compensation and is unlikely to have a material impact on shareholder value or perception.
- Employees: The transaction is specific to an executive's equity compensation and does not indicate broader changes for employees.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of earliest transaction (sale of common stock) |
| 10/02/2025 | Date the Form 4 was signed by the Attorney in Fact |
Keywords
Amylyx Pharmaceuticals, AMLX, Gina Mazzariello, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.